Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MERCK ZOCOR REDUCES RISK OF CORONARY DEATH BY 42%, OVERALL MORTALITY BY 30% -- SCANDINAVIAN STUDY; BMS SEES SIMILAR RESULTS IN PRAVACHOL STUDIES

Executive Summary

The use of Merck's Zocor (simvastatin) to treat coronary heart disease patients with mild to moderately high serum cholesterol levels resulted in a 42% drop in coronary deaths and a 30% reduction in overall mortality, according to the results of the Scandinavian Simvastatin Survival Study appearing in the Nov. 19 Lancet.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS025325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel